DOCSLIB.ORG

Important Tips in the Management of Epilepsy G P P Y Learning

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Important Tips in the Management of Epilepsy G P P Y Learning 8/24/2015 Learning Objectives for Pharmacists • List treatment pearls for common Important Tips in the issues related to the management of epilepsy in the hospital setting Managgppyement of Epilepsy • Describe alternative treatment options Deepika Pereira, Pharm.D, BCPS for epilepsy due to medication Neuro/Spine Critical Care Pharmacist Northwestern Memorial Hospital shortage issues in the hospital setting No conflicts of interest to disclose Learning Objectives for Epilepsy: Background Pharmacy Technicians • Recognize the impact of drug • Affects ~3 million people in the US each year shortages on the management of • 10% of Americans will experience a seizure sometime in their lives epilepsy in the hospital setting • 3% will receive a diagnosis of epilepsy by age • List the available dosage forms of the 80 anti-epileptic medications discussed • Encompasses different seizure types and during this presentation syndromes • Usually difficult to ascertain cause • Idiopathic (unknown cause) vs symptomatic (secondary to an identifiable condition) Epilepsy: Definitions Management of Epilepsy • Seizures: disordered, synchronous • Medication management and rhythmic firing of neurons – First unprovoked seizure thought to arise from the cerebral – Chronic epilepsy syndromes cortex – Status epilepticus • Epilepsy: disorder of brain function • Surgery characterized by the periodic and unpredictable occurrence of seizures 1 8/24/2015 Medication management Timing challenges • Status epilepticus (SE) is defined as 5 minutes or • Timing of medication administration more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent • Evidence based literature includes seizure activity without recovery between mostly expert opinion seizures • • “Animal data suggest that permanent neuronal Extensive drug-drugg, interactions, short injury and pharmacoresistance may occur before term and long term adverse effects, the traditional definition of 30 min of continuous therapeutic drug monitoring seizure activity have passed” • Control of SE should be achieved within 60 • Pharmacoresistance mintutes of onset • Drug shortages • Refractory SE is defined as those patients who have failed first 2 anti-epileptic drugs (AEDs) • Education of healthcare providers administered – Consider use of continuous infusions Tips on timing Evidence-based support • No established intravenous access – Alternate routes of benzodiazepines • Rectal diazepam • Intramuscular (IM) midazolam • IM: 2 ml in the de lto id and thigh muscles, and up to 5 ml in the gluteus maximus – Fosphenytoin is not caustic • Hemodynamically unstable patients – Use of fosphenytoin – Maximum rate: 150 mg/min Evidence-based support Evidence-based support • SE guidelines include recommendations made from the results of an international survey and expert opinion • International League Against Epilepsy updated review concluded that existing randomized controlled trials researching adult generalized tonic-clonic epilepsy are methodologically flawed and not adequate to answer important clinical questions 2 8/24/2015 Drug Metabolism Half‐life Therapeutic ADE Dosage forms Comments (hours) drug Medication profiles monitoring Pentobarbital Hydroxylated 15‐50 5‐20 mcg/ml Respiratory IV: 50 mg/ml Can mimic Drug Metabolism Half‐life Therapeutic ADE Dosage forms Comments and then depression brain death glucuronidated Cardiac depression Must be (hours) drug Paralytic ileus mechanically monitoring ventilated Fosphenytoin rapidly Conversion Free phenytoin Arrhythmias IV: 50 mg PE/ml Preferred use in Phenobarbital 50% 80‐100 10‐40 mcg/ml Sedation Oral: 20 mg/5ml solution Sequential converted via half‐life: 15 level: 1‐2 hemodynamically hydroxylated, Hypotension 15 mg, 16.2 mg, 32.4 loading if hydrolysis to minutes Total phenytoin unstable patients or 25% Respiratory mg, 60 mg, 64.8 mg, hypotensive phenytoin level: 10‐20 those with glucuronidated depression 97.2 mg and 100 mg inadequate IV access 25% excreted tablets Lacosamide 40% unchanged 13 None PR Oral: 50 mg, 100 mg, 150 Reduce dose in unchanged IV: 65 mg/ml and 130 30% O‐ prolongation mg, 200 mg tablets and severe liver cirrhosis mg/ml desmthyl‐LCM 10 mg/ml solution 50% supplemental Phenytoin 70% 20‐60 Free phenytoin Arrhythmias Oral: 50 mg chew tabs, Saturable (CYP2C19) IV: 10 mg/ml dose after dialysis hydroxylated, level: 1‐2 Hypotension 30 mg and 100 mg ER pharmacokinet then Total phenytoin Purple glove capsules, 125 mg/ml ics Levetiracetam 66% excreted 7Well Oral (IR): 250 mg, 500 Renal dose glucuronidated level: 10‐20 syndrome solution Unpredictable unchanged tolerated mg, 750 mg, 1000 mg adjustment IV: 50 mg/ml levels in 24% hydrolyzed and 100 mg/ml solution Supplemental dose uremia Oral (ER): 500 mg and adjustments after Valproate 50% 9‐16 Total valproate Hyperammonemia Oral: 125 mg sprinkle Preferred in 750 mg dialysis glucuronidated levels: Hepatotoxicity capsules, 250 mg and anoxic brain IV: 100 mg/ml sodium 50% multiple 50‐150 mcg/ml Thrombocytopenia 500 mg ER tablets, injury Lorazepam Glucuronidation 14‐18 None Hypotension Oral: 0.5 mg, 1mg, 2 mg Contains propylene other pathways 125mg, 250 mg and 500 Many 75% of Respiratory tablets and 2 mg/ml glycol including beta‐ mg DR tablets formulations metabolite depression solution oxidation 250 mg IR capsules excreted in IV: 2 mg/ml and 4 250 mg/5 ml solution urine mg/ml IV: 100 mg/ml Pharmacoresistance Pharmacoresistance • Failure of adequate trials of two • Alternative treatment options: tolerated, appropriately chosen and – Combination medication therapy administered antiepileptic drugs – Newer agents: eslicarbazepine and (whether as monotherapy or in perampanel combination) to achieve seizure freedom – Ketogenic diet • Likelihood of successful treatment – Rapid cooling with other drugs of different class – Herbal: ginger, ginseng, ginkgo biloba, diminishes kava kava, marijuana, melatonin, St. John’s wort, valerian Drug shortages Current Shortages • Defined as a supply issue that affects Drug Name Shortage date Reason how the pharmacy prepares or Divalproex sodium June 8, 2015 Product discontinued, manufacturer delay, on tablets allocation dispenses a drug product or Levetiracetam July 22, 2015 Manufacturer delay, increased demand influences patient care when injection Lorazepam July 16, 2015 Product discontinued, increased demand prescribers must use an alternative injection Valproate sodium August 11, Manufacturer delay when prescribers must use an injection 2015 alternative agent 3 8/24/2015 Alternative treatment options Resolved Shortages • Evidence based literature Drug Name Date resolved Diazepam injection October 4, 2013 Fosphenytoin injection April 2, 2015 Ketamine injection October 23, 2014 Midazolam injection August 6, 2015 Phenobarbital injection and tablets October 19, 2011 and May 8, 2014 Phenytoin injection and oral January 23, 2015 and Octiber 4, 2011 Propofol injection January 19, 2014 Topiramate capsules August 10, 2011 Topiramate sprinkle capsules April 23, 2014 Alternative treatment options Alternative treatment options • Use different agents within the same • Use different dosage forms class – Oral loading: phenytoin – Benzodiazepines • Maximum absorption= 400 mg – Barbiturates – Switch from oral solutions to tablets or – Phenytoin versus fosphenytoin capsules • dose based on drug delivery of formulation Alternative treatment options Summary • Use agents with similar mechanism of action • Management of epilepsy is complex and Drug Name Sodium channel Calcium channel GABA challenging Benzodiazepines ++ • No established guideline or literature to Carbamazepine ++ + support the use of one AED over another Lacosamide ++ *Lamotrigine ++ + • guidelines exist for the treatment of status Levetiracetam + epilepticus Oxcarbazepine ++ + • Pharmacists and technicians can make Phenobarbital ++ an impact in assisting healthcare Phenytoin ++ providers with alternatives in the setting *Topiramate+++ of drug shortages. *Valproate+++ *Broad spectrum 4 8/24/2015 CW is a 20 year old female who presents to the emergency department after a generalized tonic-clonic seizure and brief The guidelines for the management loss of consciousness. She is alert and oriented currently and of status epilepticus includes: able to tell you that she has never had a seizure before and she has been very stressed lately with finals. She has been pulling consecutive all nighters and consuming 2 pots of coffee each day. A. Only Class I, level A evidence based How would you treat CW? recommendations A. Initiate phenytoin 15 mg/kg loading dose and 100 B. Only expert opinion mg PO TID C. Some expert opinion and some Class B. Do not initiate any medication at this time I, level A evidence C. Administer lorazepam 2 mg IV push and send CW home D. Evidence that cannot be interpreted D. Initiate midazolam infusion A patient is noted to have status epilepticus Pharmacoresistance is a prevalent issue in managing epilepsy. What alternative on electroencephalogram (EEG) monitoring treatment option is recommended to but has lost IV access and the physician would like to administer medication to break overcome pharmacoresistance? the seizure now. A. Herbal supplements What medication could you provide? B. Electroconvulsive therapy A. Rectal diazepam 0.2 mg/kg C. Combining AEDs with differing B. Rectal midazolam 0.2 mg/kg mechanisms of action C. Intramuscular diazepam 0.15 mg/kg D. Warming D. Phenytoin oral loading dose 15 mg/kg Valproate sodium injection is on short supply. A patient has been on 500 mg IV References
Load more

Recommended publications
  • Kava (Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue Against Ischemic Damage in Rodents
    5 Refs: Arletti R et al, Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology 143(1), 15-19, 1999. Berger F, Handbuch der drogenkunde . Vol 2, Maudrich, Wien, 1950. Martinez M, Les plantas medicinales de Mexico . Cuarta Edicion Botas Mexico , p119, 1959. Tyler VE et al, Pharmacognosy , 9 th edition, Lea & Febiger, Philadelphia, 1988. KAVA ( Piper methysticum ) - A REVIEW The Kava plant (Piper methysticum) is a robust, well-branching and erect perennial shrub belonging to the pepper family (Piperaceae). The botanical origin remains unknown, although it is likely that early Polynesian explorers brought the plant with them from island to island. Numerous varieties of Kava exist, and today it is widely cultivated in several Pacific Island countries both for local use as well as the rapidly growing demand for pharmaceutical preparations. The dried rhizomes (roots) are normally used. The first description to the western world of the ceremonial use of an intoxicating beverage prepared from Kava was made by Captain James Cook following his Pacific voyage in 1768. The drink, prepared as an infusion in an elaborate manner after first chewing the root, is consumed on formal occasions or meetings of village elders and chiefs, as well as in reconciling with enemies and on a more social basis. It remains an important social custom in many Pacific Island countries today. Most of the islands of the Pacific possessed Kava prior to European contact, particularly those encompassed by Polynesia, Melanesia and Micronesia. After drinking the Kava beverage a pleasantly relaxed and sociable state develops, after which a deep and restful sleep occurs.
    [Show full text]
  • Alternative Treatments for Depression and Anxiety
    2019 PCB Conference: Strickland Benzodiazepines (BZDs), Herbal and Alternative Treatments for Anxiety & Depression BZD Learning Objectives • List at least three uses for benzodiazepines • Discuss at least two risk factors associated with benzodiazepine prescriptions Craig Strickland, PhD, Owner Biobehavioral Education and Consultation https://sites.google.com/site/bioedcon 1 2 BZD Pharmacokinetics Clinical Uses of BZDs Generic Name Trade Name Rapidity ½ Life Dose (mg) • Treat a variety of anxiety disorders alprazolam Xanax Intermediate Short 0.75-4 • Hypnotics • Muscle relaxants chlordiaze- Librium Intermediate Long 15-100 poxide • To produce anterograde amnesia clonazepam Klonopin Intermediate Long 0.5-4 • Alcohol & other CNS depressant withdrawal • Anti-convulsant therapy diazepam Valium Rapid Long 4-40 triazolam Halcion Intermediate Very short 0.125-0.5 temazepam Restoril Short Short 7.5-30 3 4 1 2019 PCB Conference: Strickland Issues with BZDs Herbal Medication and Alternative Therapies Used in the Treatment of Depression and Anxiety • Addictive potential • Confusion between “anti-anxiety” effects and the “warm-fuzzy) • Large dose ranges • Comparison of BZDs with medications like Buspar, etc. • They work, they work well and they work quickly 5 6 Alternative Tx. Learning Objectives Background Information on herbals: Natural does not necessarily mean “safe” • List several amino acid treatments for depression • Side-effects and adverse reactions • List at least three of the most common herbal – Herbal medications are “drugs” although
    [Show full text]
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Diazepam and Kava Combination Article
    Journal of Advanced Research (2014) 5, 587–594 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Enhanced efficacy and reduced side effects of diazepam by kava combination Rasha A. Tawfiq a, Noha N. Nassar b,*, Wafaa I. El-Eraky c, Ezzeldein S. El-Denshary b a Egyptian Patent Office, Academy of Scientific Research and Technology, 101 Kasr El-Eini St., Cairo, Egypt b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Eini St., Cairo, Egypt c Department of Pharmacology, National Research Center, El-Tahrir St., Giza, Egypt ARTICLE INFO ABSTRACT Article history: The long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com- Received 2 April 2013 binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul- Received in revised form 18 July 2013 sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam Accepted 15 August 2013 (DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups Available online 22 August 2013 as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii) received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received Keywords: (iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/ Kava kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock Diazepam seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both Anticonvulsant acute and chronic treatment.
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Effects of Low-Dose and Very Low-Dose Ketamine Among Patients with Major Depression
    International Journal of Neuropsychopharmacology Advance Access published December 17, 2015 International Journal of Neuropsychopharmacology, 2015, 1–15 doi:10.1093/ijnp/pyv124 Advance Access Publication: November 17, 2015 Review review Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis Downloaded from Ying Xu, Maree Hackett, Gregory Carter, Colleen Loo, Verònica Gálvez, Nick Glozier, Paul Glue, Kyle Lapidus, Alexander McGirr, Andrew A. Somogyi, Philip B. Mitchell, Anthony Rodgers http://ijnp.oxfordjournals.org/ The George Institute for Global Health, The University of Sydney, Sydney, Australia (Drs Xu, Hackett, and Rodgers); Centre for Translational Neuroscience and Mental Health, University of Newcastle, Australia (Dr Carter); School of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia (Drs Loo, Gálvez, and Mitchell); Brain and Mind Research Institute, University of Sydney, Australia (Dr Glozier); Department of Psychiatry, University of Otago, New Zealand (Dr Glue); Departments of Psychiatry and Neurobiology, Stony Brook University, Stony Brook, NY (Dr Lapidus); Department of Psychiatry, University of British Colombia, Canada (Dr McGirr); Discipline of Pharmacology, Faculty of Health Sciences, The University of Adelaide, Adelaide, Australia (Dr Somogyi). by Karin Lavoie on April 20, 2016 Correspondence: Colleen Loo, MD, School of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia ([email protected]). Abstract Background: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. Methods: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Analytical Studies on the Kavain Metabolism in Human Specimen and Liver Cell Lines
    Analytical studies on the kavain metabolism in human specimen and liver cell lines Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Vorgelegt von Fuad Ali Tarbah aus Derna, Libyen Düsseldorf 2003 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. Th. Daldrup Korreferent: Prof. Dr. G. Willuhn, Prof. Dr. H. Weber Tag der mündlichen Prüfung: 17. 12. 2003 Parts of this Ph.D. Thesis have already been presented and/or published in: Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Mass spectral characterisation of hepatic cell metabolites of D,L-kavain using HPLC and GC/MS systems. Special issue: 37th TIAFT triennial meeting “Problems of Forensic Sciences” XLII: 173-180 (1999) Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Determination of D,L-kavain and its metabolites in blood, serum and urine. Rapid quantitative method using fluid/fluid extraction and gas chromatography/mass spectrometry (GC/MS). Poster in 79. Jahrestagung der Deutschen Gesellschaft für Rechtsmedizin, Medizinische Einrichtungen der Universität / Gesamthochschule Essen (2000) Tarbah F., Mahler H., Kardel B., Weinmann W., Hafner D. and Daldrup Th. Kinetics of kavain and its metabolites after oral application. J. Chromatogr. B 789 (1): 115-130 (2003) Cabalion P., Barguil Y., Duhet D., Mandeau A., Warter S., Russmann S., Tarbah F. and Daldrup Th. Kava in modern therapeutic uses: to a better evaluation
    [Show full text]
  • Potential Benefits of Ketamine Seen in Antidepressent Clinical Trial
    Clin. Invest. (2013) 3(7), 609–612 NEWS Highlights from the latest news and research in Clinical Investigation Potential benefits of ketamine seen in antidepressent clinical trial The largest clinical trial to date utiliz- TX, USA) and James Murrough (Mount placebo-administered group. For both ing the anesthetic ketamine was led by Sinai, NY, USA) along with their research groups the drugs were well tolerated. researchers from the Icahn School of team. Seventy two patients with treat- Murrough summarized the study Medicine (Mount Sinai, NY, USA). ment-resistant depression (classified as findings, “We found that ketamine was The clinical trial enrolled patients diag- failure to respond to two or more med- safe and well tolerated and that patients nosed with treatment-resistant major ications) were evaluated and underwent who demonstrated a rapid antidepressant depression who were treated with ket- either a single intravenous infusion of effect after starting ketamine were able amine – and within 24 h the antide- ketamine over the course of 40 minutes to maintain the response throughout the pressant benefits of the anesthetic were or were treated with the active placebo course of the study.” He also added that reported. Traditional antidepressants midazolam. Midazolam is also an anes- for future studies, “Larger placebo-con- can normally take between several days thetic but does not possess antidepressant trolled studies will be required to more to weeks to demonstrate an improvement properties. Patients were interviewed after fully determine the safety and efficacy in depression. 24 h, and then again after 7 days had profile of ketamine in depression.” passed.
    [Show full text]
  • Piper Methysticum) in Rats
    Graduate Theses, Dissertations, and Problem Reports 2008 Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R. Bruner West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Bruner, Natalie R., "Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats" (2008). Graduate Theses, Dissertations, and Problem Reports. 4358. https://researchrepository.wvu.edu/etd/4358 This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R. Bruner Thesis submitted to the Eberly College of Arts and Sciences at West Virginia University in Partial Fulfillment of the Requirements for the Degree of Master of Science in Psychology Karen G. Anderson, Ph. D., Chair Kennon A. Lattal, Ph.D. Hawley Montgomery-Downs, Ph.D. Department of Psychology Morgantown, WV 2008 Keywords: drug discrimination, kava, chlordiazepoxide ABSTRACT Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R.
    [Show full text]
  • Piper Methysticum)
    Journal of Student Research (2015) Volume 4, Issue 2: pp. 69-72 Research Article A Closer Look at the Risks vs. Benefits of Kava (Piper methysticum) Anan A. Husseina If you took a trip to Fiji, the locals would probably welcome you with a drink of Kava. For centuries, the indigenous people of the South Pacific Islands have used the roots of a plant known as Kava. Beyond the use of Kava as a psychoactive substance, it has been incorporated as a cultural drink that is used in many ceremonies. In the late 1990’s Kava use spread quickly in Western countries including Europe, North America, and Australia. It was used as a treatment for anxiety. But just as quickly as it spread, the enthusiasm for it faded, because it was banned or restricted in many Western countries following reports of liver toxicity. In the United States, the Food and Drug Administration’s (FDA) concern for safety prompted a request for more research on the substance. The issues of safety and efficacy remain more specifically whether the benefits of using Kava outweigh the risks. History Kava is a beverage made from the roots of the plant included alcohol, cocaine, tobacco, and heroin. The findings Piper methysticum, and has been used historically in the suggest that kava may reduce the craving associated with the South Pacific Islands as a ceremonial drink. Kava was aforementioned substances, which may make kava a great introduced in Europe around the 1700s by Captain James future candidate to help with addiction. 13 Cook and has since spread widely to Australia, Europe, and Although the mechanism of action is not clear, it is the United States.
    [Show full text]
  • (6)-Kavain on Voltage-Activated Inward Currents of Dorsal Root Ganglion Cells from Neonatal Rats
    European Neuropsychopharmacology 9 (1999) 171±176 Short communication Effects of (6)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats K. Schirrmachera,* , D. BusselbergÈ 1,a , J.M. Langosch b , J. Walden b , U. Winter c , D. Bingmann a aInstitut f urÈÈ Physiologie, Universitat-GH Essen, Hufelandstrasse 55, 45122 Essen, Germany bPsychiatrische UniversitatsklinikÈ , 79104 Freiburg, Germany cKrewel Meuselbach GmbH, 53783 Eitorf, Germany Received 21 November 1997; accepted 20 January 1998 Abstract Kava pyrones extracted from pepper Piper methysticum are pharmacologically active compounds. Since kava pyrones exhibit anticonvulsive, analgesic and centrally muscle relaxing properties, the in¯uence of a synthetic kava pyrone, (6)-kavain, on voltage- dependent ion channel currents was studied. Effects of (6)-kavain on voltage-activated inward currents were analysed in cultured dorsal root ganglion cells derived from neonatal rats. Voltage-activated Ca211 and Na currents were elicited in the whole-cell con®guration of the patch clamp technique. Extracellularly applied (6)-kavain dissolved in hydrous salt solutions reduced voltage-activated Ca21 and Na1 channel currents within 3±5 min. As the solubility of (6)-kavain in hydrous solutions is low, dimethyl sulfoxide (DMSO) was added to the saline as a solvent for the drug in most experiments. When (6)-kavain was dissolved in DMSO, the drug induced a fast and pronounced reduction of both Ca211 and Na currents, which partly recovered within 2±5 min even in the presence of the drug. The present study indicates that (6)-kavain reduces currents through voltage-activated Na1 and Ca21 channels. 1999 Elsevier Science B.V./ECNP.
    [Show full text]